Skip to content

Effect and Mechanism of M1-rTMS in Regulating Cortical Networks to Ameliorate Chronic Pain-Associated Central Sensitization

Effect and Mechanism of M1-rTMS in Regulating Cortical Networks to Ameliorate Chronic Pain-Associated Central Sensitization - Effect and Mechanism of M1-rTMS in Regulating Cortical Networks to Ameliorate Chronic Pain-Associated Central Sensitization

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116685
Enrollment
Unknown
Registered
2026-01-13
Start date
2026-01-25
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central sensitization related to chronic pain

Interventions

HF-rTMS group:Healthy subjects were randomly assigned to receive the high - frequency repetitive transcranial magnetic stimulation (HF - rTMS) protocol. The coil was positioned over the left primary m
stimulus frequency, 10 Hz
pulses per train, 10
number of trains, 16
inter - train interval, 26 s
stimulus intensity, 80% of the resting motor threshold (RMT).
Sham group:Healthy subjects were randomly assigned to receive the sham protocol. During sham stimulation, the coil was positioned at a 90° angle to the scalp
the number of pulses per train was 10, the number of trains was 16, the inter-train interval was 26 s, and the stimulus intensity was set at 80% of the resting motor threshold (RMT).

Sponsors

Guangdong Provincial People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 20 and <= 60 years, either sex. 2. Right-handed. 3. No history of chronic pain. 4. Has understood the study’s purpose and procedures, agreed to undergo evaluation, treatment and follow-up, and signed the informed-consent form.

Exclusion criteria

Exclusion criteria: 1. Known allergy to capsaicin; 2. History of skin disorders on the forearm; 3. History of neurological disease; 4. History of epileptic seizures; 5. Metallic implants in the head, neck, or chest; 6. Any other contraindication to TMS evaluation or treatment; 7. Use of analgesic or psychotropic medication within one month before study participation.

Design outcomes

Primary

MeasureTime frame
CPM function score;

Secondary

MeasureTime frame
Visual Analog Scale;fNIRS brain functional imaging ;

Countries

China

Contacts

Public ContactXu Guangqing

Guangdong Provincial People’s Hospital

guangchingx@163.com+86 189 8899 1969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026